Alternative names
5-MeO-DALT
IUPAC Name
2-(3-fluorophenyl)-3-methylmorpholine
Current Scheduling Status
None
Year(s) and type of review / ECDD meetings
Drug Class
Recommendation (from TRS)
Substance identification
5-Methoxy-N,N-diallyltryptamine (abbreviation: 5-MeO-DALT; chemical name: N-allyl-N-(2-(5-methoxy-1H-indol-3-yl)ethyl)prop-2-en-1-amine) is a synthetic hallucinogen. It is a solid, crystalline powder described as white, off-white, grey, light brown or tan. It has also been found as yellow, purple or green tablets.
WHO review history
5-MeO-DALT has not been formally reviewed by WHO and is not currently under international control. Information was brought to WHO’s attention that this substance is manufactured clandestinely, poses a risk to public health and has no recognized therapeutic use.
Similarity to known substances and effects on the central nervous system
5-MeO-DALT has a chemical structure similar to that of the hallucinogen 3-[2-(dimethylamino)ethyl]indole (DMT), which is listed under Schedule I of the Convention on Psychotropic Substances of 1971. 5-MeO-DALT binds to various receptors, with no clear mechanism of action; the receptors include serotoninergic, adrenergic, histamine, kappa opioid receptors and sigma receptors, as well as the dopamine and serotonin transporters (DAT and SERT).
Its pharmacological profile in studies in laboratory animals indicates that the effects of 5-MeO-DALT are consistent with those of hallucinogens such as (−)-2,5-dimethoxy-4-methylamphetamine (DOM) and lysergic acid diethylamide (LSD), although some effects differ from those of other hallucinogens.
Dependence potential
No controlled experimental studies to determine the probable dependence potential of 5-MeO-DALT have been reported, although unvalidated reports on online forums describe the development of tolerance when 5-MeO-DALT was used daily. As it is similar to DOM, 5-MeO-DALT would be expected to have little potential to produce dependence.
Actual abuse and/or evidence of likelihood of abuse
Preclinical studies suggest that 5-MeO-DALT has abuse potential, as it shares discriminative stimulus effects with DOM. No studies to determine the abuse liability of 5-MeO-DALT in humans have been reported. 5-MeO-DALT is sold online, and sales and seizures have been reported in many countries in several regions. A few reports have been made of adverse effects, including agitation and aggression, related to possible use of 5-MeO- DALT. The presence of the substance was not, however, biologically confirmed in the majority of cases.
Therapeutic usefulness
5-MeO-DALT is not known to have any therapeutic use.
Recommendation
5-Methoxy-N,N-diallyltryptamine or 5-MeO-DALT (chemical name: N-allyl- N-(2-(5-methoxy-1H-indol-3-yl)ethyl)prop-2-en-1-amine)) is a synthetic hallucinogen with some effects similar to those of other hallucinogens such as DOM that are controlled under Schedule I of the 1971 Convention on Psychotropic Substances. Its mode of action is unclear, and there is very limited information on its effects in humans. While its use may constitute a risk to public health, the current evidence is insufficient to recommend international control.
Recommendation: The Committee recommended that 5-methoxy-N,N- diallyltryptamine (5-MeO-DALT, chemical name: N-allyl-N-(2-(5-methoxy- 1H-indol-3-yl)ethyl)prop-2-en-1-amine)) be kept under surveillance by the WHO Secretariat.
5-Methoxy-N,N-diallyltryptamine (abbreviation: 5-MeO-DALT; chemical name: N-allyl-N-(2-(5-methoxy-1H-indol-3-yl)ethyl)prop-2-en-1-amine) is a synthetic hallucinogen. It is a solid, crystalline powder described as white, off-white, grey, light brown or tan. It has also been found as yellow, purple or green tablets.
WHO review history
5-MeO-DALT has not been formally reviewed by WHO and is not currently under international control. Information was brought to WHO’s attention that this substance is manufactured clandestinely, poses a risk to public health and has no recognized therapeutic use.
Similarity to known substances and effects on the central nervous system
5-MeO-DALT has a chemical structure similar to that of the hallucinogen 3-[2-(dimethylamino)ethyl]indole (DMT), which is listed under Schedule I of the Convention on Psychotropic Substances of 1971. 5-MeO-DALT binds to various receptors, with no clear mechanism of action; the receptors include serotoninergic, adrenergic, histamine, kappa opioid receptors and sigma receptors, as well as the dopamine and serotonin transporters (DAT and SERT).
Its pharmacological profile in studies in laboratory animals indicates that the effects of 5-MeO-DALT are consistent with those of hallucinogens such as (−)-2,5-dimethoxy-4-methylamphetamine (DOM) and lysergic acid diethylamide (LSD), although some effects differ from those of other hallucinogens.
Dependence potential
No controlled experimental studies to determine the probable dependence potential of 5-MeO-DALT have been reported, although unvalidated reports on online forums describe the development of tolerance when 5-MeO-DALT was used daily. As it is similar to DOM, 5-MeO-DALT would be expected to have little potential to produce dependence.
Actual abuse and/or evidence of likelihood of abuse
Preclinical studies suggest that 5-MeO-DALT has abuse potential, as it shares discriminative stimulus effects with DOM. No studies to determine the abuse liability of 5-MeO-DALT in humans have been reported. 5-MeO-DALT is sold online, and sales and seizures have been reported in many countries in several regions. A few reports have been made of adverse effects, including agitation and aggression, related to possible use of 5-MeO- DALT. The presence of the substance was not, however, biologically confirmed in the majority of cases.
Therapeutic usefulness
5-MeO-DALT is not known to have any therapeutic use.
Recommendation
5-Methoxy-N,N-diallyltryptamine or 5-MeO-DALT (chemical name: N-allyl- N-(2-(5-methoxy-1H-indol-3-yl)ethyl)prop-2-en-1-amine)) is a synthetic hallucinogen with some effects similar to those of other hallucinogens such as DOM that are controlled under Schedule I of the 1971 Convention on Psychotropic Substances. Its mode of action is unclear, and there is very limited information on its effects in humans. While its use may constitute a risk to public health, the current evidence is insufficient to recommend international control.
Recommendation: The Committee recommended that 5-methoxy-N,N- diallyltryptamine (5-MeO-DALT, chemical name: N-allyl-N-(2-(5-methoxy- 1H-indol-3-yl)ethyl)prop-2-en-1-amine)) be kept under surveillance by the WHO Secretariat.
ECDD Recommendation
Placed under surveillance
Link to full TRS
9789240023024-eng.pdf1.84 MB
MS Questionnaire Report